<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Technetium Tc-99m exametazime: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Technetium Tc-99m exametazime: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Technetium Tc-99m exametazime: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="17081" href="/d/html/17081.html" rel="external">see "Technetium Tc-99m exametazime: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F20452813"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ceretec;</li>
<li>Drax Exametazime</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52914227"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Ceretec</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F13186280"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Radiopharmaceutical</li></ul></div>
<div class="block doa drugH1Div" id="F13186423"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="93545e54-cbb9-4bd6-9812-ad78a31e8b2e">Cerebral perfusion imaging, stroke</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cerebral perfusion imaging, stroke:</b>
<b>IV</b> (based on a 70 kg patient): 15 to 30 mCi (555 to 1110 MBq). Perform imaging 30 to 90 minutes after administration and complete imaging within 4 hours after administration; planar or SPECT imaging techniques may be utilized.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5546e75d-e23a-4a5d-a3b7-3e9067362c8d">Cerebral perfusion imaging, non-stroke</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cerebral perfusion imaging, non-stroke (off-</b>
<b>label use):</b>
<b>IV:</b> 15 to 30 mCi (555 to 1,110 MBq); images obtained after 40 minutes will be interpretable; however, images obtained after 90 minutes will provide the best quality (ACR/SPR 2016; Juni 2009).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="94604dd7-6413-4b47-80c7-f9b5a026e41f">Leukocyte-labeled scintigraphy in intra-abdominal infection/inflammatory bowel disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leukocyte-labeled scintigraphy in intra-abdominal infection/inflammatory bowel disease:</b>
<b>IV:</b> Tc 99m-labeled leukocytes: 5 to 10 mCi (185 to 370 MBq). Dynamic imaging may be performed for the first 60 minutes after administration; static imaging may be performed at 30 to 90 minutes, 2 to 4 hours, and if necessary, 18 to 24 hours after administration.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d573bbb-33df-4259-9db4-76568cf2e684">Leukocyte-labeled scintigraphy in non-abdominal infection/inflammation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leukocyte-labeled scintigraphy in non-abdominal infection/inflammation (off-label use): IV:</b> Tc 99m-labeled leukocytes: 5 to 10 mCi (185 to 370 MBq); obtain delayed imaging at 4 to 8 hours; if early images are negative, longer imaging time (16 to 24 hours) may be necessary (Palestro 2004).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990865"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Risk for toxicities may be increased in patients with renal impairment; Tc 99m is substantially excreted by the kidney. There are no specific dosage adjustments provided in the manufacturer's labeling; however, dose reduction may be considered if an adequate number of labeled white blood cells are administered.</p></div>
<div class="block doha drugH1Div" id="F50988143"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F58683556"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F51976321"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f7d993b3-1c45-42f7-abcb-f3a64885dc41">Cerebral perfusion imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cerebral perfusion imaging (stroke):</b> Children ≥2 years and Adolescents: IV: 0.4 mCi/kg (14 MBq/kg); minimum dose of 3 mCi (110 MBq); do not exceed maximum administered activity for an adult. Perform imaging 30 to 90 minutes after administration and complete imaging within 4 hours after administration; planar or SPECT imaging techniques may be utilized.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="94604dd7-6413-4b47-80c7-f9b5a026e41f">Leukocyte-labeled scintigraphy in intra-abdominal infection/inflammatory bowel disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leukocyte-labeled scintigraphy in intra-abdominal infection/inflammatory bowel disease:</b> Children ≥2 years and Adolescents: IV: 0.2 mCi/kg (7.4 MBq/kg); minimum dose of 2 mCi (74 MBq); do not exceed maximum administered activity for an adult. Dynamic imaging may be performed for the first 60 minutes after administration; static imaging may be performed at 30 to 90 minutes, 2 to 4 hours, and if necessary, 18 to 24 hours after administration.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F13186438"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Facial edema, transient hypertension</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Erythema, skin rash</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F22367899"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer’s labeling. </p></div>
<div class="block war drugH1Div" id="F13186336"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis, may occur. Emergency resuscitation equipment and personnel should be immediately available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Radiation accumulation: Tc 99m administration contributes to the patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Risk is greater with pediatric patients due to greater radiosensitivity and longer life expectancy. Ensure safe handling to minimize radiation exposure to the patient and health care providers.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Substantially excreted by the kidney; risk for toxicities may be increased in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and health care personnel. Use under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority. <b>Note:</b> Contents of kit are not radioactive; however, adequate shielding is required after addition of radioactive material.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Instruct patients to void when examination is completed, and frequently thereafter; encourage adequate hydration to facilitate frequent voiding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Risk for misinterpretation: Image interpretation errors may occur with Tc 99m exametazime; images may be affected by the presence of tumor, infarction, trauma, and other inflammatory conditions.</p></div>
<div class="block foc drugH1Div" id="F20452814"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Kit, Intravenous [preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">Ceretec: (5s) [vial contents to be combined with sodium pertechnetate Tc 99m injection solution (not included)]</p>
<p style="text-indent:-2em;margin-left:4em;">Drax Exametazime: (5s) [vial contents to be combined with sodium pertechnetate Tc 99m injection solution (not included)]</p></div>
<div class="block geq drugH1Div" id="F20452812"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block adm drugH1Div" id="F20222939"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Follow manufacturer's labeling for administration. Ensure adequate hydration after administration. Instruct patient to void within 2 hours after administration to minimize radiation exposure (Juni 2009); patients should void frequently to minimize kidney and bladder exposure.</p>
<p style="text-indent:-2em;margin-left:2em;">Leukocyte-labeled scintigraphy: Administer using a 19-gauge needle as soon as possible (preferably within 20 minutes but no later than 1 hour) after preparation of the Tc 99m labeled leukocyte suspension.</p>
<p style="text-indent:-2em;margin-left:2em;">Radiopharmaceutical; use appropriate precautions for handling and disposal. Ensure adequate hydration before and after administration.</p></div>
<div class="block admp drugH1Div" id="F52614494"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Radiopharmaceutical; use appropriate precautions for handling and disposal. Use waterproof gloves and effective radiation shielding, including syringe shields, when handling.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Contents of kit are used to prepare technetium Tc 99m exametazime and are not for direct IV injection; only reconstituted technetium Tc 99m exametazime may be administered IV. Follow manufacturer's labeling for administration. Ensure adequate hydration after administration. Instruct patient to void prior to and within 2 hours after administration to minimize radiation exposure (Juni 2009); patients should void frequently to minimize kidney and bladder exposure.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Leukocyte-labeled scintigraphy:</i> Administer using a 19-gauge needle as soon as possible (preferably within 20 minutes but no later than 1 hour) after preparation of the Tc 99m labeled leukocyte suspension.</p></div>
<div class="block use drugH1Div" id="F13186286"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Imaging agent:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Leukocyte labeled scintigraphy: Adjunct in the localization of intra-abdominal infection and inflammatory bowel disease in adults (Ceretec and Drax Exametazime) and pediatric patients ≥2 years of age (Ceretec only).</p>
<p style="text-indent:-2em;margin-left:4em;">Cerebral scintigraphy: Ceretec: Adjunct in the detection of altered regional cerebral perfusion in stroke patients ≥2 years of age.</p></div>
<div class="block off-label drugH1Div" id="F25744926"><span class="drugH1">Use: Off-Label: Adult</span><p>Cerebral perfusion imaging (non-stroke); Non-abdominal infection sites (localization)</p></div>
<div class="block mst drugH1Div" id="F13255273"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F57529618"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F57529615"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F53623749"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Pregnancy status should be evaluated prior to use in women of reproductive potential (SNM 2010).</p></div>
<div class="block pri drugH1Div" id="F13186379"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Technetium Tc 99m exametazime crosses the placenta (Owunwanne 1998); the amount of technetium Tc 99m that can be detected in fetal tissue depends upon the specific formulation, route of administration, and stage of pregnancy (Adelstein 1999).</p>
<p style="text-indent:0em;margin-top:2em;">In general, the potential for a radiopharmaceutical to cause fetal harm depends on the dose absorbed by the fetus and the stage of pregnancy. High doses of radiopharmaceuticals used for therapeutic procedures are more likely to result in fetal harm. A medically required diagnostic procedure can usually be modified to decrease fetal risk. Elective diagnostic procedures should be delayed until after delivery (ACR-SPR 2018; Adelstein 1999; ICRP 2000; SNM 2010).</p></div>
<div class="block brc drugH1Div" id="F13186398"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">In a case report, a breastfeeding mother was administered technetium Tc 99m exametazime 500 mBq IV for a brain perfusion study (postpartum age not presented). Peak activity in the breast milk was detected 6.5 hours after the injection, and the calculated effective dose (0.26 mSv) was low enough that an interruption of breastfeeding would not have been necessary (Marshall 1996).</p>
<p style="text-indent:-2em;margin-left:2em;">Available guidance recommends that lactating women interrupt breastfeeding for a period of 12 to 24 hours after administration of Tc 99m exametazime (depending on the dose) (IAEA 2018). During this time, women can continue to express milk at normal feeding times and discard the milk until breastfeeding can be resumed. Alternatively, women can pump and store breast milk prior to the procedure, which can be bottle-fed (Harding 1995).</p>
<p style="text-indent:-2em;margin-left:2em;">Elective diagnostic procedures should be delayed until breastfeeding has stopped (SNM 2010). Women who are breastfeeding and caring for individuals undergoing nuclear medicine procedures do not need any additional precautions (ABM [Mitchell 2019]).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion of technetium Tc 99m into colostrum is widely variable and information is limited; therefore, recommendations related to early breastfeeding cannot be made (Mountford 1989; Rubow 1994).</p></div>
<div class="block mop drugH1Div" id="F22367909"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;">Monitor for signs/symptoms of hypersensitivity</p></div>
<div class="block pha drugH1Div" id="F22367901"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Radioactive diagnostic agent which decays by isomeric transition to emit a photon that can be detected by imaging </p></div>
<div class="block phk drugH1Div" id="F22367902"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Distributes to brain, muscle, and soft tissue </p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Physical: ~6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (~50%); Urine (~40%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23777092"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Brain spect | Ceretec | Leuco scint</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ceretec</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cerestab | Ceretec</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Ceretec</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ceretec</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cerebrotec | Ceretec</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ceretec</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ceretec</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ceretec</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ceretec</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-10331526">
<a name="10331526"></a>Adelstein SJ. Administered radionuclides in pregnancy. <i>Teratology. </i>1999;59(4):236-239.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-exametazime-drug-information/abstract-text/10331526/pubmed" id="10331526" target="_blank">10331526</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American College of Radiology (ACR)/Society for Pediatric Radiology (SPR) Practice Parameter for the Performance of Single Photon Emission Computed Tomography (SPECT) Brain Perfusion Imaging, including Brain Death Examinations. 2016. https://www.acr.org/-/media/ACR/Files/Practice-Parameters/brainperf-spect.pdf?la=en. Accessed March 7, 2018.</div>
</li>
<li>
<div class="reference">
                  American College of Radiology (ACR), Society for Pediatric Radiology (SPR). ACR–SPR practice parameter for imaging pregnant or potentially pregnant adolescents and women with ionizing radiation (resolution 39). Revised 2018. https://www.acr.org/-/media/ACR/Files/Practice-Parameters/Pregnant-Pts.pdf?la=en. Accessed February 24, 2020.</div>
</li>
<li>
<div class="reference">
                  Ceretec (technetium Tc exametazime) [prescribing information]. Arlington Heights, IL: GE Healthcare Medi-Physics, Inc; September 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DraxExametazime.1">
<a name="DraxExametazime.1"></a>Drax Exametazime (technetium Tc exametazime) [prescribing information]. Kirkland, Quebec, Canada: Jubilant DraxImage; August 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DraxExametazimeCAN.1">
<a name="DraxExametazimeCAN.1"></a>Drax Exametazime (technetium Tc exametazime) [product monograph]. Kirkland, Quebec, Canada: Jubilant DraxImage; January 2020.</div>
</li>
<li>
<div class="reference">
                  Harding LK, Bossuyt S, Pellet C, et al. Recommendations for nuclear medicine physicians regarding breastfeeding mothers. <i>Eur J Nucl Med.</i> 1995;22(5)BP17.</div>
</li>
<li>
<div class="reference">
                  International Atomic Energy Agency. <i>IAEA Safety Standards for Protecting People and the Environment: Radiation Protection and Safety in Medical Uses of Ionizing Radiation. Specific Safety Guide No. SSG-46</i>. IAEA; 2018. https://www​.iaea.org​/publications/11102/radiation-protection-and-safety-in-medical-uses-of-ionizing-radiation.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11108925">
<a name="11108925"></a>International Commission on Radiological Protection (ICRP). Pregnancy and medical radiation. <i>Ann ICRP.</i> 2000;30(1):iii-viii, 1-43. doi:10.1016/s0146-6453(00)00037-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-exametazime-drug-information/abstract-text/11108925/pubmed" id="11108925" target="_blank">11108925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19692453">
<a name="19692453"></a>Juni JE, Waxman AD, Devous MD Sr, et al. Procedure guideline for brain perfusion SPECT using (99m)Tc radiopharmaceuticals 3.0. <i>J Nucl Med Technol.</i> 2009;37(3):191-195. doi:10.2967/jnmt.109.067850<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-exametazime-drug-information/abstract-text/19692453/pubmed" id="19692453" target="_blank">19692453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8929318">
<a name="8929318"></a>Marshall DS, Newberry NR, Ryan PJ. Measurement of the secretion of technetium-99m hexamethylpropylene amine oxime into breast milk. <i>Eur J Nucl Med</i>. 1996;23(12):1634-1635.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-exametazime-drug-information/abstract-text/8929318/pubmed" id="8929318" target="_blank">8929318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31107104">
<a name="31107104"></a>Mitchell KB, Fleming MM, Anderson PO, Giesbrandt JG; Academy of Breastfeeding Medicine. ABM Clinical Protocol #31: radiology and nuclear medicine studies in lactating women. <i>Breastfeed Med</i>. 2019;14(5):290‐294. doi:10.1089/bfm.2019.29128.kbm<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-exametazime-drug-information/abstract-text/31107104/pubmed" id="31107104" target="_blank">31107104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2645546">
<a name="2645546"></a>Mountford PJ, Coakley AJ. A review of the secretion of radioactivity in human breast milk: data, quantitative analysis and recommendations. <i>Nucl Med Commun.</i> 1989;10(1):15-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-exametazime-drug-information/abstract-text/2645546/pubmed" id="2645546" target="_blank">2645546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9776293">
<a name="9776293"></a>Owunwanne A, Omu A, Patel M, et al. Placental Binding and Transfer of Radiopharmaceuticals: Technetium-99m d, 1-HMPAO. <i>J Nucl Med.</i> 1998;39(10):1810-1813.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-exametazime-drug-information/abstract-text/9776293/pubmed" id="9776293" target="_blank">9776293</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Palestro CJ, Brown ML, Forstrom LA, et al. Society of Nuclear Medicine Procedure Guideline for <sup>99m</sup>Tc-Exametazime (HMPAO)-Labeled Leukocyte Scintigraphy for Suspected Infection/Inflammation. 2004. http://interactive.snm.org/docs/HMPAO_v3.pdf. Accessed March 7, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8162938">
<a name="8162938"></a>Rubow S, Klopper J, Wasserman H, et al. The excretion of radiopharmaceuticals in human breast milk: additional data and dosimetry. <i>Eur J Nucl Med.</i> 1994;21(2):144-153.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/technetium-tc-99m-exametazime-drug-information/abstract-text/8162938/pubmed" id="8162938" target="_blank">8162938</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16805 Version 98.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
